Notice Information
Notice Title
Onasemnogene Abeparvovec Intravenous (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service
Notice Description
Onasemnogene abeparvovec intravenous (Zolgensma(r)) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE's technology appraisal programme, with an expected final guidance publication date in late 2026.
Lot Information
Lot 1
Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)
Options: Contract period for 3 years with the option to extend up to 2 additional years
Renewal: Commissioners may decide to to renew the contract at the end of its term
Lot 2Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)
Options: Contract period for 3 years with the option to extend up to a further 2 years
Renewal: Commissioners may decide to to renew the contract at the end of its term
Lots 3Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)
Options: Contract period for 3 years with the option to extend up to a further 2 years
Renewal: Commissioners may decide to to renew the contract at the end of its term
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-06ae08
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/053026-2026
- Current Stage
- Tender
- All Stages
- Tender
Procurement Classification
- Notice Type
- Tender Notice
- Procurement Type
- Standard
- Procurement Category
- Services
- Procurement Method
- Open
- Procurement Method Details
- Open procedure
- Tender Suitability
- Not specified
- Awardee Scale
- Not specified
Common Procurement Vocabulary (CPV)
- CPV Divisions
85 - Health and social work services
-
- CPV Codes
85100000 - Health services
Notice Value(s)
- Tender Value
- £26,136,000 £10M-£100M
- Lots Value
- £26,136,000 £10M-£100M
- Awards Value
- Not specified
- Contracts Value
- Not specified
Notice Dates
- Publication Date
- 4 Jun 20261 weeks ago
- Submission Deadline
- 8 Jul 20264 weeks to go
- Future Notice Date
- Not specified
- Award Date
- Not specified
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Active
- Lots Status
- Active
- Awards Status
- Not Specified
- Contracts Status
- Not Specified
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS ENGLAND
- Contact Name
- Available with D3 Tenders Premium →
- Contact Email
- Available with D3 Tenders Premium →
- Contact Phone
- Available with D3 Tenders Premium →
Buyer Location
- Locality
- LONDON
- Postcode
- SE1 8UG
- Post Town
- South East London
- Country
- England
-
- Major Region (ITL 1)
- TLI London
- Basic Region (ITL 2)
- TLI4 Inner London - East
- Small Region (ITL 3)
- TLI45 Lambeth
- Delivery Location
- Not specified
-
- Local Authority
- Lambeth
- Electoral Ward
- Waterloo & South Bank
- Westminster Constituency
- Vauxhall and Camberwell Green
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-06ae08-2026-06-04T16:37:40+01:00",
"date": "2026-06-04T16:37:40+01:00",
"ocid": "ocds-h6vhtk-06ae08",
"description": "Spinal muscular atrophy (SMA) is a rare genetic disorder that causes muscle weakness and progressive loss of movement. The severity of SMA can vary greatly between individuals. Historically, the condition has been classified into different types, determined by clinicians at the time of diagnosis. This classification is based on both the age at which symptoms first appear, and the highest level of motor function achieved by the patient. <br/><br/>The types range from type 0, the most severe form, where symptoms are present before birth and most affected infants do not survive past 6 months, through to type 4, which develops in adulthood and is associated with mild motor impairment and a normal life span. However, because the disease presents so variably, consistently categorising patients into these types at the point of diagnosis can be challenging. <br/><br/>Onasemnogene abeparvovec intravenous (Zolgensma(r)) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE's technology appraisal programme, with an expected final guidance publication date in late 2026. <br/><br/>This procurement is based on Lots with the intention to cover the population served by NHS England.<br/><br/>The objective is to allow Bidders to apply for different Lots that align best with their service capability and capacity.<br/><br/>Lots:<br/>Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)<br/><br/>Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)<br/><br/>Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)<br/><br/><br/><br/><br/>To express interest and participate in the Competitive Process, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome Should Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at:<br/><br/>Phone: 08000988201<br/>E-mail: support-health@atamis.co.uk<br/><br/>The closing date for completed Competitive Process responses is 12:00pm (noon), on Wednesday 8 July 2026.<br/><br/>Atamis Project reference C449537.<br/><br/>The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).<br/><br/>This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to<br/>the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply.",
"initiationType": "tender",
"tender": {
"id": "ocds-h6vhtk-06ae08",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "Onasemnogene Abeparvovec Intravenous (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service",
"status": "active",
"classification": {
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
},
"mainProcurementCategory": "services",
"description": "Onasemnogene abeparvovec intravenous (Zolgensma(r)) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE's technology appraisal programme, with an expected final guidance publication date in late 2026.",
"value": {
"amount": 26136000,
"currency": "GBP"
},
"lots": [
{
"id": "0",
"title": "Lot 1",
"description": "Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)",
"value": {
"amount": 8527000,
"currency": "GBP"
},
"contractPeriod": {
"durationInDays": 1800
},
"hasRenewal": true,
"renewal": {
"description": "Commissioners may decide to to renew the contract at the end of its term"
},
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "Contract period for 3 years with the option to extend up to 2 additional years"
},
"status": "active"
},
{
"id": "3",
"title": "Lot 2",
"description": "Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)",
"value": {
"amount": 8283000,
"currency": "GBP"
},
"contractPeriod": {
"durationInDays": 1800
},
"hasRenewal": true,
"renewal": {
"description": "Commissioners may decide to to renew the contract at the end of its term"
},
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "Contract period for 3 years with the option to extend up to a further 2 years"
},
"status": "active"
},
{
"id": "1 and 2",
"title": "Lots 3",
"description": "Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)",
"value": {
"amount": 9326000,
"currency": "GBP"
},
"contractPeriod": {
"durationInDays": 1800
},
"hasRenewal": true,
"renewal": {
"description": "Commissioners may decide to to renew the contract at the end of its term"
},
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "Contract period for 3 years with the option to extend up to a further 2 years"
},
"status": "active"
}
],
"items": [
{
"id": "0",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "0"
},
{
"id": "3",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "3"
},
{
"id": "1 and 2",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"relatedLot": "1 and 2"
}
],
"submissionMethod": [
"electronicSubmission",
"written"
],
"submissionMethodDetails": "https://atamis-1928.my.site.com/s/Welcome",
"communication": {
"atypicalToolUrl": "https://atamis-1928.my.site.com/s/Welcome"
},
"procurementMethod": "open",
"procurementMethodDetails": "Open procedure",
"coveredBy": [
"GPA"
],
"tenderPeriod": {
"endDate": "2026-07-08T12:00:00+01:00"
},
"submissionTerms": {
"languages": [
"en"
],
"bidValidityPeriod": {
"durationInDays": 180
}
},
"awardPeriod": {
"startDate": "2026-07-08T13:00:00+01:00"
},
"bidOpening": {
"date": "2026-07-08T13:00:00+01:00"
},
"hasRecurrence": true
},
"parties": [
{
"id": "GB-FTS-130973",
"name": "NHS England",
"identifier": {
"legalName": "NHS England"
},
"address": {
"streetAddress": "Wellington House, 133-135 Waterloo Rd",
"locality": "London",
"region": "UKI",
"postalCode": "SE1 8UG",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Surinder Kahlon",
"email": "surinder.kahlon@nhs.net",
"url": "https://atamis-1928.my.site.com/s/Welcome"
},
"roles": [
"buyer"
],
"details": {
"url": "https://www.england.nhs.uk/",
"buyerProfile": "https://www.england.nhs.uk/",
"classifications": [
{
"id": "BODY_PUBLIC",
"scheme": "TED_CA_TYPE",
"description": "Body governed by public law"
},
{
"id": "07",
"scheme": "COFOG",
"description": "Health"
}
]
}
},
{
"id": "GB-FTS-141301",
"name": "NHS Arden and Greater East Midlands Commissioning Support Unit",
"identifier": {
"legalName": "NHS Arden and Greater East Midlands Commissioning Support Unit"
},
"address": {
"streetAddress": "Cardinal Square, 10 Nottingham Road",
"locality": "Derby",
"postalCode": "DE1 3QT",
"countryName": "United Kingdom"
},
"roles": [
"reviewBody"
],
"details": {
"url": "https://www.ardengemcsu.nhs.uk/"
}
}
],
"buyer": {
"id": "GB-FTS-130973",
"name": "NHS England"
},
"language": "en"
}